Press Release: Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company’s Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab…
Press Release: Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - Newscast
Sun, 02 Mar 2025 10:48:00 GMT Therapeutics announced positive data on measurements of disease control and quality of life from the Company’s Phase 2 ...
Sat, 01 Mar 2025 23:59:00 GMT Celldex (CLDX) Therapeutics announced positive data on measurements of disease control and quality of life from the Company’s Phase 2 barzolvolimab studies in patients with chronic urticaria.
Fri, 28 Feb 2025 16:00:00 GMT - Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life ...
Thu, 27 Feb 2025 13:01:00 GMT Enrollment ongoing in Phase 3 barzolvolimab CSU studies ... autoimmune and other devastating diseases. Visit www.celldex.com. This release contains "forward-looking statements" made pursuant ...
Thu, 30 Jan 2025 17:20:00 GMT Barzolvolimab, Celldex's lead product, is a c-KIT antibody currently in Phase 3 trials for CSU. The drug has shown promising results in treating both CSU and CIndU, conditions characterized by ...
